Edwards Lifesciences Corporation $EW Shares Sold by Capital Insight Partners LLC

Capital Insight Partners LLC lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 20.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,076 shares of the medical research company’s stock after selling 10,231 shares during the quarter. Capital Insight Partners LLC’s holdings in Edwards Lifesciences were worth $3,039,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in Edwards Lifesciences in the 2nd quarter valued at $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Edwards Lifesciences by 127.5% during the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after buying an additional 3,864,908 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Edwards Lifesciences by 15.7% during the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after buying an additional 1,584,958 shares in the last quarter. Finally, Holocene Advisors LP raised its position in shares of Edwards Lifesciences by 35.2% in the second quarter. Holocene Advisors LP now owns 4,703,977 shares of the medical research company’s stock valued at $367,898,000 after buying an additional 1,223,460 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the sale, the vice president directly owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 45,465 shares of company stock valued at $3,804,610 over the last 90 days. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on EW shares. Robert W. Baird set a $87.00 price target on shares of Edwards Lifesciences and gave the stock a “neutral” rating in a research report on Tuesday, December 16th. BTIG Research reissued a “buy” rating and issued a $103.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Wells Fargo & Company set a $100.00 target price on Edwards Lifesciences in a report on Thursday. Mizuho upped their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Finally, Barclays reiterated an “overweight” rating and set a $103.00 price objective (up previously from $99.00) on shares of Edwards Lifesciences in a research report on Monday, December 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.95.

Edwards Lifesciences Trading Up 1.0%

Shares of Edwards Lifesciences stock opened at $85.66 on Monday. The stock has a 50 day moving average of $82.53 and a 200 day moving average of $79.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The firm has a market capitalization of $49.71 billion, a price-to-earnings ratio of 36.92, a PEG ratio of 3.85 and a beta of 0.97. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.